SWOG 80702: Overview of Study Design, Efficacy End Points and Patient Characteristics

Panelists discuss how SWOG 80702, a large-scale randomized clinical trial, employed a robust factorial design with clearly defined efficacy end points including disease-free and overall survival while enrolling a diverse patient population with stage III colon cancer to evaluate optimal adjuvant therapy duration and the impact of celecoxib.

EP: 1.The Role of ctDNA in CRC

EP: 2.BESPOKE: Study Design, Efficacy End Points, and Methods

EP: 3.Overview of BESPOKE Patient Characteristics

EP: 4.BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

EP: 5.BESPOKE: ctDNA Clearance During and After ACT

EP: 6.Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy

Now Viewing

EP: 7.SWOG 80702: Overview of Study Design, Efficacy End Points and Patient Characteristics

EP: 8.SWOG 80702: Impressions on the Efficacy Data

Recent Videos